Detalhe da pesquisa
1.
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
Cancer
; 130(3): 421-432, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37846845
2.
Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
Haematologica
; 109(2): 591-603, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37534514
3.
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.
Haematologica
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38813706
4.
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
Ann Hematol
; 103(4): 1305-1315, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38049586
5.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(4): 523-533, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38247315
6.
Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.
Ann Hematol
; 102(11): 3195-3204, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37679605
7.
More accurate prediction of treatment response than mean apparent diffusion coefficient value in multiple myeloma using whole body MRI histogram analysis.
Future Oncol
; 19(17): 1175-1185, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37386939
8.
Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.
J Transl Med
; 20(1): 576, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36494694
9.
Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
Ann Hematol
; 101(6): 1201-1210, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35437610
10.
Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study.
Age Ageing
; 51(1)2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34673897
11.
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
Br J Haematol
; 194(5): 862-869, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34328213
12.
IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Eur J Haematol
; 105(3): 326-334, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32421883
13.
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities.
Haematologica
; 109(5): 1619-1623, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235518
14.
Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial.
Haematologica
; 109(5): 1614-1618, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38205507
15.
Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: a case report and literature review.
Ann Hematol
; 103(1): 339-341, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743381
16.
Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
Ann Hematol
; 94(2): 257-64, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25231928
17.
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Biol Blood Marrow Transplant
; 20(3): 319-25, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24296491
18.
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
Haematologica
; 99(2): 353-9, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24213147
19.
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.
Ther Adv Med Oncol
; 16: 17588359231221340, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38249329
20.
Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
J Immunother Cancer
; 12(3)2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443094